Alnylam Pharmaceuticals has capped off a busy month of breakthrough therapy recipients, with the company announcing the designation May 31 for its ALN-AS1 (givosiran) an RNAi treatment designed for the prevention of attacks in patients with acute hepatic porphyria.
US FDA's Record-Breaking Month Of Breakthrough Therapy Designations
Alnylam's ALN-AS1 became the eighth announced therapy to receive a breakthrough designation in May 2017, breaking the previously monthly high of seven.